Garching / Munich, Germany, September 16, 2025 – ITM, a prominent radiopharmaceutical biotech firm, confirmed today its plans to present dosimetry findings from its recently completed Phase 3 COMPETE trial. This presentation will occur during an oral session at the European Association of Nuclear Medicine (EANM) congress, which is scheduled from October 4 to October 8, 2025, in Barcelona, Spain. Additionally, ITM will be hosting a satellite symposium focused on targeted theranostics for neuroendocrine tumors (NETs) and conducting “Meet the Expert” sessions at its dedicated conference booth.
Oral Presentation Details
The oral presentation, titled “Dosimetry of [177Lu]Lu-edotreotide in patients with grade 1 or grade 2 gastro-enteropancreatic neuroendocrine tumours: Results from the COMPETE Phase 3 trial,” will be given by Dr. Emmanuel Deshayes. Dr. Deshayes is an Associate Professor of Nuclear Medicine at the Faculty of Medicine, Montpellier, France, and also serves as the Principal Investigator for the COMPETE study site at the Institut de Recherche en Cancérologie de Montpellier (IRCM).
Presentation ID: OP-429
Date and Time: Monday, October 6, 2025 from 3:00 pm – 3:10 pm CEST
Session: Clinical Oncology Track – TROP Session – Oncology & Theranostics Committee: NET and PRRT
Location: Room 117
Satellite Symposium Details
The ITM-hosted event, “SSTR-Targeting Theranostics in NETs and Beyond: Milestones and New Frontiers,” will be presided over by Dr. Ken Herrmann, who chairs the Nuclear Medicine Department at the University Hospital Essen. Dr. Herrmann, alongside a panel of expert speakers, will delve into the advancement and growing clinical significance of the investigational agent 177Lu-edotreotide in managing NETs. Discussions will cover its scientific foundations and the existing evidence supporting its application in gastroenteropancreatic NETs, in addition to examining prospective advancements in SSTR-targeted therapies.
Speakers and Topics
- From Concept to Clinic: the Origins of 177Lu-edotreotide in NETs
Prof. Vikas Prasad, M.D., PhD; Nuclear Medicine, Mallinckrodt Institute of Radiology, St. Louis, USA
- Translating Evidence into Practice: the Role of 177Lu-edotreotide in NETs
Dr. Rocío García-Carbonero, M.D., PhD; Medical Oncology, University Hospital 12 de Octubre, Madrid, Spain
- Exploring the Future of the SSTR-Targeting Landscape
Prof. Damian Wild, M.D., PhD; Nuclear Medicine, University Hospital Basel, Basel, Switzerland
Date and Time: Sunday, October 5, 2025 from 1:30 pm – 2:30 pm CEST
Location: Room 114
Meet the Expert Sessions
ITM plans to conduct two “Meet the Expert” sessions featuring Dr. Julia Fricke, who hails from the Clinic for Radiology and Nuclear Medicine at the University Hospital Basel, Switzerland. During these sessions, Dr. Fricke will elaborate on ITM’s theranostic pair, ITM-63/ITM-64, developed for the diagnosis and treatment of SSTR+ tumors. ITM-63 is a therapeutic agent employing Terbium-161, currently undergoing preclinical evaluation, while ITM-64 serves as its companion diagnostic, based on Gallium-68, and is in Phase 1 clinical assessment. Notably, Dr. Fricke was honored with the EANM Marie Curie Award last year for her presentation regarding ITM-63.
Session 1 Date and Time: Sunday, October 5, 4:30 pm – 5:00 pm CEST
Session 2 Date and Time: Monday, October 6, 9:30 am – 10:00 am CEST
Location: ITM Booth #71
About the COMPETE Trial
The COMPETE trial (NCT03049189) assessed 177Lu-edotreotide (ITM-11), which is a proprietary, synthetic, targeted investigational radiotherapeutic agent. It was compared against everolimus, a targeted molecular therapy, in patients presenting with inoperable, progressive Grade 1 or Grade 2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The study achieved its primary endpoint, showing that 177Lu-edotreotide delivered a clinically and statistically significant enhancement in progression-free survival (PFS) when compared to everolimus. Furthermore, 177Lu-edotreotide is currently undergoing evaluation in COMPOSE, another Phase 3 study involving patients diagnosed with well-differentiated, aggressive Grade 2 or Grade 3, SSTR-positive GEP-NET tumors.
About ITM Isotope Technologies Munich SE
ITM, a preeminent radiopharmaceutical biotech firm, is committed to delivering innovative radiopharmaceutical therapeutics and diagnostics for challenging-to-treat tumors. Our objective is to address the requirements of cancer patients, clinicians, and partners by excelling in the development, manufacturing, and worldwide distribution of medical radioisotopes. With enhanced patient benefit as its core philosophy, ITM is progressing a comprehensive precision oncology pipeline, encompassing numerous Phase 3 studies, which integrates the company’s superior radioisotopes with various targeting molecules. Capitalizing on its two decades of groundbreaking radiopharma proficiency, pivotal industry standing, and extensive global infrastructure, ITM endeavors to offer patients more efficacious targeted treatments to elevate clinical results and overall quality of life.
ITM Contact
Corporate Communications
Kathleen Noonan/Julia Westermeir
Phone: +49 89 329 8986 1500
Email:
Investor Relations
Ben Orzelek
Phone: +49 89 329 8986 1009
Email:
Attachment
